Astragaloside IV induces endothelial progenitor cell angiogenesis in deep venous thrombosis through inactivation of PI3K/AKT signaling

Authors: Xiaojiang Lyu, Zhigang Yi, Yun He, Chunfeng Zhang, Ping Zhu and Chonghai Liu

DOI: 10.14670/HH-18-704
Article type: ORIGINAL ARTICLE
Accepted: 2024-01-05
Epub ahead of print: 2024-01-05
**Astragaloside IV induces endothelial progenitor cell angiogenesis in deep venous thrombosis through inactivation of PI3K/AKT signaling**

Xiaojiang Lyu#, Zhigang Yi#, Yun He, Chunfeng Zhang, Ping Zhu, Chonghai Liu*

Department of Pediatrics, Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, China.

#These authors contributed equally to this work.

*Corresponding author: Affiliated Hospital of North Sichuan Medical College, 1 Maoyuan South Road, Shunqing District, Nanchong, China. E-mail: liuchdoctor@hotmail.com.

**Abstract**

**Background:** Deep vein thrombosis (DVT), referred to as venous thromboembolism, is the third most frequent cardiovascular disease. Endothelial progenitor cells (EPCs) contribute to the recanalization of DVT. Astragaloside IV (AS-IV) has been suggested to have angiogenesis-enhancing effects. Here, we investigate the roles and mechanisms of AS-IV in EPCs and DVT.

**Methods:** The experimental DVT model was established by inferior vena cava stenosis in rats. EPCs were collected from patients with DVT. Transwell assays were performed to detect cell migration. Tube formation was determined using Matrigel basement membrane matrix and ImageJ software. The thrombus weight and length were measured. Pathological changes were examined by hematoxylin-eosin staining. The production of proinflammatory cytokines was estimated by ELISA. The level of PI3K/AKT-related proteins was measured by western blotting.

**Results:** AS-IV administration facilitated the migrative and angiogenic functions of human EPCs *in vitro*. Additionally, AS-IV inhibited thrombosis and repressed the infiltration of leukocytes into the thrombus and the production of proinflammatory cytokines in rats. Mechanistically, AS-IV inactivated PI3K/AKT signaling in rats.

**Conclusion:** AS-IV prevents thrombus in an experimental DVT model by facilitating EPC angiogenesis and decreasing inflammation through inactivation of PI3K/AKT signaling.
Key words: deep venous thrombosis; Astragaloside IV; angiogenesis; leukocytes; inflammation; PI3K/AKT

Introduction
Deep venous thrombosis (DVT) is an obstructive disease with a hindering venous reflux mechanism. It usually involves the lower limb venous system, with clot formation originating in a deep calf vein and propagating proximally (Chen et al., 2022). DVT is a common venous thromboembolic disorder affecting 1.6 per 1000 people annually (Albricker et al., 2022). Post-thrombotic syndrome (PTS), including chronic pain, edema, and leg ulceration, occurs in 43% of patients within two years post-DVT, and 40% of patients presenting with proximal DVT develop a pulmonary embolism. The recurrence of DVT is up to 25% (Waheed et al., 2023). As reported, DVT represents the third most common cause of death from cardiovascular disease after heart attacks and stroke. Even in patients who do not get pulmonary emboli, recurrent thrombosis and PTS are major causes of death (Naringrekar et al., 2019; Parker and Thachil 2018; Seifi et al., 2018; Naringrekar et al., 2019). Currently, effective therapeutic options for DVT include anticoagulation, thrombectomy, and pharmacologic thrombolysis (Fuchs et al., 2012). However, these therapeutic methods have the risk of major hemorrhage and wound complications (Kim et al., 2015). Thus, finding novel effective agents for treating DVT is urgent.

Angiogenesis is a critical player in thrombus recanalization (Li and Li, 2016). Endothelial progenitor cells (EPCs) are vascular endothelial precursor cells characterized by their potential to self-renew, migrate, and develop into mature endothelial cells, which have therapeutic efficacies in cardiovascular diseases (Lo Gullo et al., 2018). Accumulating evidence has articulated that recruitment of EPCs to thrombi accelerates thrombus resolution, which is beneficial for DVT treatment (Kong et al., 2016a,b; Li and Li, 2016). Moreover, EPCs are involved in the angiogenesis and repair of injured vasculature (Miller-Kasprzak and Jagodziński, 2007). However, the clinical applications of EPCs face many challenges (Hou and Li, 2018); therefore, the exploration of the mechanism regulating EPC functions is crucial.

Inflammation plays a critical role in the development of DVT (Liu et al., 2020a). Under pathological conditions, the venous vascular endothelium is activated and recruits leukocytes,
which can release proinflammatory cytokines such as TNF-α, IL-1β, and IL-6 (Angona et al., 2015). Neutrophils, monocytes, and lymphocytes are three major types of leukocytes and can reflect the inflammation, malnutrition, and immune status of patients (Schrottmaier et al., 2020). The number of neutrophils, monocytes, and lymphocytes increased after DVT onset (Feng et al., 2017). Consequently, a reduction in leukocytes is essential to treat DVT. Astragaloside IV (AS-IV) isolated from *astragaloside* has been widely used in treating cardiovascular disease in China. Its antioxidant, anti-inflammatory, and anti-apoptotic properties have been well established (Ren et al., 2013; Liu et al., 2020b). AS-IV has been found to suppress the inflammatory response in human bronchial epithelial cells (Hsieh et al., 2022). The water-soluble derivative of AS-IV, astragalosidic acid, shares a similar structure with AS-IV and has a preventive effect on arachidonic acid-induced thrombosis in zebrafish (Wu et al., 2022). Moreover, AS-IV enhances the angiogenic function of adipose-derived mesenchymal stem cells in a hindlimb ischemia model (Wang et al., 2022), accelerates bone regeneration through inducing osteogenesis and angiogenesis (Wang et al., 2021c), and improves angiogenesis in diabetic rats (Wang et al., 2021b). However, the biological functions of AS-IV in DVT remain uncertain. Collectively, this study was designed to examine the effect of AS-IV on DVT. Phosphoinositide 3-kinase (PI3K)/AKT signaling is involved in the regulation of inflammation, and its activation is associated with thrombosis (Chang et al., 2016). Therefore, this study explores whether the effects of AS-IV on DVT development are mediated by PI3K/AKT signaling. Our findings may contribute to the development of a novel effective treatment for DVT.

**Methods**

**Animals**

Sprague-Dawley (SD) rats (male, 200-250 g; SJA Laboratory Animal CO., LTD, Hunan, China) were housed in a specific pathogen-free room with a controlled temperature of 22±2°C and 55±5% humidity under a 12-h light/dark cycle. All rats were given free access to a regular rodent diet. All experiments involving animals were approved by the Animal Ethics Committee of the Affiliated Hospital of North Sichuan Medical College, and all experimental protocols strictly followed the Guide for the Care and Use of Laboratory Animals published by the National
Establishment of the experimental DVT model

After one week of acclimation, rats received overnight fasting. Then, the rats were anesthetized with pentobarbital sodium (36 mg/kg; Sigma-Aldrich, Shanghai, China). Subsequently, the rats underwent a midline laparotomy to expose the inferior vena cava (IVC). Thereafter, the IVC was ligated with 7-0 Prolene sutures, and the posterior venous branches were tightened (Yang et al. 2020b). Then, the confluence in the iliac vein was clamped with vascular clips for 15 min. Finally, the incision was sutured, and ceftriaxone sodium (TopScience, Shanghai, China) was used to prevent bacterial infection. The sham operation included the same surgical procedure without IVC stenosis.

Animal groupings

There were a total of 30 rats recruited in this study. Animals were randomly divided into four groups: (a) the sham group, rats received sham operation; (b) the Thrombotic group, rats underwent IVC stenosis; (c) the Thrombotic + DMSO group, rats were administrated 400 µL dimethyl sulfoxide (DMSO; MedChemExpress, Shanghai, China) orally for 14 days after thrombosis induction; (d) the Thrombotic + AS-IV group, AS-IV dry powder (purity: ≥ 98%) purchased from MedChemExpress was dissolved and diluted with DMSO, and rats were administered 10 mg/kg/day AS-IV in DMSO orally for 14 days after thrombosis induction. A total of five rats died during model establishment (one during operation, two the day after operation, and two three days post-operation). Each group had six rats. The dose of AS-IV was chosen according to a previous study (Qin et al. 2022).

Sample collection

On day 14 post-operation, the animals were intraperitoneally injected with 1% pentobarbital sodium and venous plasma was harvested from the IVC using a vacuum blood tube without anticoagulants. Thereafter, rats were euthanized by decapitation after deep anesthesia. Afterward, after the removal of excessive blood on the thrombi, the IVC containing the thrombus was carefully removed for weight and length assessment. IVCs were split into two
parts after clearing unclotted blood: one was fixed with 4% paraformaldehyde for histopathologic analysis and the other was stored at -80°C for western blotting and ELISA.

**Histologic analyses**

After fixation in 4% paraformaldehyde for 48 h, IVCs were dehydrated with graded alcohol, mounted in paraffin, and cut into sections of 4 µm thickness. The sections were then deparaffinized and stained with hematoxylin (Sigma-Aldrich) for 15 min and eosin (Sigma-Aldrich) for 40 s. An optical microscope (Olympus, Tokyo, Japan) was applied to count and sum the neutrophils, monocytes, and lymphocytes from five high-power fields (HPFs).

**ELISA**

The collected venous plasma was centrifuged at 1600 ×g for 10 min at 4°C. The serum levels of TNF-α, IL-1β, and IL-6 were assayed with ELISA kits (Multi Sciences, Hangzhou, China). The absorbance value at 450 nm was read via a microplate reader (BioTek, Winooski, VT, USA). The minimum detectable level of the kits for TNF-α, IL-1β, and IL-6 was 0.43, 1.42, and 2.57 pg/mL, respectively.

**Western blotting**

The frozen IVCs were lysed using RIPA buffer (Sigma-Aldrich) for the isolation of total protein, and the BCA Protein Assay Kit (Innochem, Beijing, China) was utilized to measure the protein concentration. Thereafter, proteins (40 µg) were separated by SDS-PAGE and blotted onto a PVDF membrane. After blocking with 5% skimmed milk for two hours, the membrane was incubated overnight with primary antibodies against phosphorylated PI3K (ab182651, 1:500; Abcam), PI3K (ab191606, 1:1000; Abcam), phosphorylated AKT (ab81283, 1:5000; Abcam), AKT (ab233755, 1:2000; Abcam), GAPDH (ab181603, 1:10000; Abcam) at 4°C, and subsequently incubated with the respective secondary antibodies for 2 h at room temperature. After washing with TBST (Sigma-Aldrich) three times, the bands were visualized by an enhanced chemiluminescence reagent (Beyotime, Shanghai, China), and the blot intensity was quantified by Image Lab 3.0 software (Bio-Rad, Hercules, CA, USA).
**Isolation of EPCs**

Ten patients aged 18-60 years with newly diagnosed first idiopathic DVT of the lower limbs at the Affiliated Hospital of North Sichuan Medical College were included in this study. However, patients who had received anticoagulant drugs or undergone surgery prior to blood collection, and patients with a history of diabetes mellitus, hypertension, and other chronic diseases were excluded from this study. The DVT symptoms in enrolled patients lasted 21 days. The protocol was approved by the ethics review committee of the Affiliated Hospital of North Sichuan Medical College. All participants provided their written informed consent. EPCs were isolated as previously described (Zhang et al., 2018). First, peripheral blood (80 mL from each subject) was collected from 10 patients, and peripheral blood mononuclear cells (PBMCs) were isolated through density gradient centrifugation using Histopaque-1077 (Sigma-Aldrich) and then seeded into FN-coated six-well dishes (2×10^7 cells/well). Primary cells were incubated with endothelial cell basal medium-2 (EGM-2; Lonza, Walkersville, MD, USA) supplemented with 10% fetal bovine serum (FBS; Sigma-Aldrich). After four days of incubation, non-adherent cells were removed using phosphate-buffered saline (PBS; Sigma-Aldrich), and new medium was applied. Thereafter, the medium was refreshed every two days. Cells at passage 3 were used for subsequent experiments. To detect the biological functions of AS-IV, EPCs were treated with or without AS-IV (100 µM) (Hsieh et al., 2022).

**Transwell detection of cell migration**

Cell migration was examined by a Transwell system (Corning, NY, USA). The isolated EPCs were plated into the top compartment containing Matrigel (Sigma-Aldrich), and EGM-2 medium containing 20% FBS was added to the lower reservoir. The cells migrated to the lower surface of the chamber filter after 24 h of incubation were fixed and stained with hematoxylin. An optical microscope was used to measure the number of EPCs penetrating the membrane of three random fields.

**Tube formation assay**

EPCs were seeded into 24-well plates (5×10^4 cells/well) coated with Matrigel (80 µL/well) at 37°C. After 24 h of incubation, tube-like structures were monitored using an inverted optical
microscope (Leica, Wetzlar, Germany) and images were processed using ImageJ software.

**Statistics analysis**
All experiments were performed with at least three independent repeats. Statistical analysis was analyzed using GraphPad Prism 8 (GraphPad Software, San Diego, CA, USA). Data were described as the mean ± standard deviation. One-way analysis of variance followed by Tukey’s post hoc analysis and Student’s t-test were used for comparison analyses. p<0.05 was considered statistically significant.

**Results**

**AS-IV facilitates human EPC migration and angiogenesis**
Figure 1A shows the chemical structure of AS-IV. Peripheral blood was collected from 10 patients with newly diagnosed DVT to isolate EPCs, and human EPCs at passage 3 were used in this study. The effects of AS-IV on human EPC migration and angiogenesis were detected. As Transwell assays revealed, the AS-IV-treated human EPCs exhibited enhanced migrative capability compared with EPCs without AS-IV treatment (Fig 1B-C). The angiogenic function of human EPCs was strengthened in the presence of AS-IV as evidenced by increased tube-like structures and tube length (Fig 1D-F). These results demonstrate that AS-IV enhances the angiogenic function of human EPCs.

**AS-IV inhibits thrombus formation and leukocyte infiltration into thrombi in rats**
DVT rat models were administrated AS-IV or DMSO orally for 14 days after thrombosis induction. The representative images of thrombi are presented in Figure 2A. Thrombus weight and size were significantly increased after IVC stenosis, whereas AS-IV administration abolished this increase in tumor weight and size (Fig. 2B-C). Compared with sham-operated rats, DVT rat models showed augmented thrombosis in IVC, whereas administration of AS-IV attenuated the thrombosis (Fig. 2D). Leukocytes are associated with an increased risk of venous thrombosis (Kushnir et al. 2016). More leukocytes were recruited to thrombi after IVC stenosis. However, AS-IV administration markedly reduced the influxes of neutrophils, monocytes, and lymphocytes to thrombi (Fig. 2E-G). These results suggest that AS-IV treatment may inhibit
thrombosis and suppress leukocyte infiltration into thrombi in rats.

**AS-IV prevents the production of proinflammatory cytokines in rats**

Leukocytes release proinflammatory cytokines such as TNF-α, IL-1β, and IL-6 (Swystun and Liaw 2016). The serum levels of these proinflammatory cytokines were remarkably upregulated in experimental DVT rat models, whereas administration of AS-IV in DVT rats attenuated this promotion (Fig 3A-C).

**AS-IV inactivates PI3K/AKT signaling in rats**

Mechanistically, IVC stenosis caused an increase in the phosphorylation of PI3K and AKT, whereas AS-IV treatment counteracted the pathway-activating effects of IVC stenosis, as western blotting revealed (Fig 4A-C). Taken together, AS-IV deactivates PI3K/AKT signaling.

**Discussion**

DVT is a common life-threatening disorder with a significant mortality rate. In patients with proximal DVTs, 40% are likely to develop pulmonary embolism. Death occurs in approximately 6% of DVT cases and 12% of pulmonary embolism cases within one month of diagnosis (Waheed et al. 2023). The existing therapeutic options have side effects. Thus, we explored novel agents for DVT treatment. AS-IV exerts protective effects against cardiovascular diseases, including heart dysfunction (Wang et al., 2021d), myocardial hypertrophy (Zhang et al., 2020), cardiomyocyte injury induced by ischemia (Huang et al., 2021a), hypoxia/reoxygenation (Yang et al., 2020a), and doxorubicin (Luo et al., 2021). However, the biological functions of AS-IV in DVT pathogenesis remain unknown. Herein, we found that AS-IV administration reduced thrombus weight and length and attenuated thrombosis in a rat model of DVT, then we investigated the mechanisms by which AS-IV mitigated thrombosis.

EPCs are critical in vascular intima repair, reendothelialization of denuded vessels, and angiogenesis, and their migration into thrombi leads to recanalization (Zilla et al., 2007). AS-IV reverses the inhibitory effects of high glucose on the migration of keratinocytes (Gao et al., 2022), promotes the migration of adipose-derived mesenchymal stem cells (Wang et al., 2022),
enhances the migration and tube formation functions of high glucose-treated human umbilical vein endothelial cells (HUVECs) (Zou et al., 2022), and recovers the migrative ability of oxidized low-density lipoprotein-treated EPCs and HUVECs (Qian et al., 2019; Shao et al., 2021). Additionally, AS-IV improves the angiogenesis of EPCs around the wound (Huang et al., 2021b), promotes the angiogenesis of vascular endothelial cells in hypoxic conditions (Wang et al., 2021a), and enhances the angiogenesis of HUVECs after myocardial infarction (Cheng et al., 2019). This study showed that AS-IV administration recovered the migrative and tube formation abilities of EPCs, which was similar to previous findings.

The intricate relationship between inflammation and thrombosis is mediated by the endothelium, leukocytes, and platelets. Leukocytes are involved in venous thromboembolism, and leukocyte-derived particles are associated with increased thrombus formation (Galeano-Valle et al., 2021). AS-IV treatment reduces inflammatory cell infiltration and inflammatory cytokine production in experimental colitis (Zhong et al., 2022), myocardial ischemia/reperfusion injury (He et al., 2022), and asthma (Yang and Wang, 2019). The current study demonstrated that AS-IV administration decreased the infiltration of neutrophils, monocytes, and lymphocytes into the thrombus and prevented the release of TNF-α, IL-1β, and IL-6, indicating that AS-IV treatment relieved the IVC stenosis-induced inflammation in the thrombus and serum.

The PI3K/AKT pathway is suggested to regulate cell proliferation, cell apoptosis, and inflammatory response (Involvement of pro-inflammatory cytokines in diabetic neuropathic pain via central PI3K/Akt/mTOR signal pathway 2021; Zhang et al., 2019). Inhibition of PI3K/AKT signaling is associated with attenuation of platelet aggregation and thrombus formation, while activation of PI3K/AKT induces endothelial damage, apoptosis, and inflammation (Chang et al., 2016; Su et al., 2016). AS-IV is found to inactivate the PI3K/AKT pathway to improve hematoma absorption after intracerebral hemorrhage and prevent PM2.5-induced lung injury (Pei et al., 2021; Zheng et al., 2022). Herein, AS-IV administration reduced the phosphorylation of PI3K and AKT, suggesting that AS-IV inactivated PI3K/AKT signaling.

In the present study, there are some limitations. First, although it seems that AS-IV could have some benefits in the treatment of DVT, these investigations have not yet been performed in humans, and the side effects of AS-IV are, as yet, unknown in humans. Second, different doses
of AS-IV have not been tested. Third, we have not studied the effect of AS-IV on rats after PI3K/AKT inhibitors were used. Moreover, the value of adjuvant AS-IV during other thrombectomy methods in treating DVT should be addressed in the future.

In conclusion, this study demonstrates that AS-IV mitigates thrombosis in an experimental DVT model by promoting EPC angiogenesis and preventing inflammation \textit{in vivo} through inactivating PI3K/AKT signaling. This study provides experimental data for the prevention and treatment of DVT and provides new avenues for further research.

\textbf{Ethical approval}

All experiments involving animals were approved by the Animal Ethics Committee of the Affiliated Hospital of North Sichuan Medical College, and all experimental protocols strictly followed the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health (NIH publication no.85-23, revised 1996).

\textbf{Consent to participation}

The protocol was approved by the ethics review committee of the Affiliated Hospital of North Sichuan Medical College. All participants provided their written informed consent.

\textbf{Consent to publication}

Not applicable.

\textbf{Availability of data and material}

The datasets used or analyzed during the current study are available from the corresponding author upon reasonable request.

\textbf{Competing interest}

The authors declare that they have no competing interests.
Funding
This work was supported by a special research project from the research fund of the Sichuan Medical Association (Hengrui) (No.2021HR36).

Acknowledgments
The authors appreciate the help of the Affiliated Hospital of North Sichuan Medical College.

Authors’ contribution
Xiaojiang Lyu and Zhigang Yi conceived and designed the experiments. Xiaojiang Lyu, Zhigang Yi, Yun He, Chunfeng Zhang, Ping Zhu, and Chonghai Liu carried out the experiments. Xiaojiang Lyu, Zhigang Yi, and Chonghai Liu analyzed the data. Xiaojiang Lyu, Zhigang Yi, and Chonghai Liu drafted the manuscript. All authors agreed to be accountable for all aspects of the work. All authors have read and approved the final manuscript.

Figure legends
Fig 1. AS-IV facilitates human EPC migration and angiogenesis.
(A) The chemical structure of AS-IV. (B-C) Peripheral blood was collected from 10 patients with newly diagnosed DVT to isolate EPCs, and human EPCs at passage 3 were used. The migrative capability of human EPCs with or without AS-IV treatment was detected by Transwell assays. (D) The in vitro tube formation assay was used to determine the angiogenesis ability of human EPCs. (E-F) Quantification of tube formation and length. AS-IV, Astragaloside IV; EPC, endothelial progenitor cells. Data are expressed as mean ± standard deviation from three independent experiments. **p<0.01 compared with the Control group.

Fig 2. AS-IV inhibits thrombus formation and infiltration of leukocytes into thrombi in rats.
(A) DVT rat models were administrated AS-IV or DMSO orally for 14 days after thrombosis induction. Representative images of the thrombus at day 14 after IVC stenosis are shown. (B-C) Quantification of thrombus weight and length. (D) The pathological changes were observed through the H&E staining of serial cross-sections of IVC. (E) Neutrophil infiltration into the
thrombus. (F) Monocyte filtration into the thrombus. (G) Lymphocyte infiltration into the thrombus. AS-IV, Astragaloside IV; DMSO, dimethyl sulfoxide; H&E, hematoxylin-eosin. Data are expressed as mean ± standard deviation from three independent experiments. N=6 for each group. ***p<0.001 compared with the Sham group, **p<0.01 compared with the Thrombotic group. Low magnification: scale bar = 100 µm; high magnification: scale bar = 20 µm.

**Fig 3. AS-IV prevents the production of proinflammatory cytokines in rats.**

(A) Serum level of TNF-α; (B) IL-1β; and (C) IL-6. AS-IV, Astragaloside IV; TNF-α, tumor necrosis factor-α; IL-1β, interleukin-1β; IL-6, interleukin-6. Data are expressed as mean ± standard deviation from three independent experiments. N=6 for each group. **p<0.01 compared with the Sham group, ***p<0.001 compared with the Thrombotic group.

**Fig 4. AS-IV inactivates PI3K/AKT signaling in rats.**

(A-C) The protein levels of p-PI3K, PI3K, p-AKT, and AKT in thrombi were measured by western blotting. AS-IV, Astragaloside IV; PI3K, phosphoinositide 3-kinase; AKT, protein kinase B. Data are expressed as mean ± standard deviation from three independent experiments. N=6 for each group. **p<0.01, ***p<0.001 compared with the Sham group, ##p<0.01 compared with the Thrombotic group.

References


PI3K/Akt signalings, cytotoxicity and IL-8 production in endothelial cells. Oncotarget 7, 74473-74483.


Copyright © 2023, StatPearls Publishing LLC., Treasure Island (FL) ineligible companies.

Disclosure: Pujitha Kudaravalli declares no relevant financial relationships with ineligible companies. Disclosure: David Hotwagner declares no relevant financial relationships with ineligible companies.


myocardial hypertrophy induced by mechanical stress by activating autophagy and reducing inflammation. Am. J. Transl. Res. 12, 5332-5342.


Astragaloside IV Chemical Structure

Control

AS-IV

E

F

Tube-like structure per field

Relative total length per field